1. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.
- Author
-
Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, and Kohno M
- Subjects
- Antibiotics, Antineoplastic pharmacology, Cell Line, Tumor, Humans, Phosphatidylinositol 3-Kinases physiology, Proto-Oncogene Proteins c-akt physiology, Signal Transduction drug effects, Apoptosis drug effects, Chromones pharmacology, Doxorubicin pharmacology, Morpholines pharmacology, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Signal Transduction physiology, Tumor Suppressor Protein p53 physiology
- Abstract
Constitutive activation of the PI3 kinase/Akt pathway is associated with the neoplastic phenotype of a large number of human tumor cells. As the anti-apoptotic role of the PI3 kinase/Akt pathway has been established, we have examined whether specific blockade of this pathway sensitizes tumor cells to DNA-damaging agent-induced cytotoxicity by enhancing apoptotic cell death. Although a PI3 kinase inhibitor, LY294002, by itself does not induce apoptotic cell death, LY294002 selectively and markedly enhances the apoptosis-inducing efficacy of doxorubicin: such an enhanced cell death is only detected in tumor cells in which the PI3 kinase/Akt pathway is constitutively activated, and it is totally dependent on the functional p53 pathway. These results suggest that the combination of a PI3 kinase/Akt pathway inhibitor and doxorubicin provides an efficient chemotherapeutic strategy for the treatment of tumor cells in which the PI3 kinase/Akt pathway is constitutively activated and the p53 pathway is functional.
- Published
- 2006
- Full Text
- View/download PDF